#### 5 Claims:

## 1. A thiomorpholino steroid compound of general formula I

HO
$$\begin{array}{c}
C^9 \\
C^8 \\
C^8
\end{array}$$

$$\begin{array}{c}
C^{14} \\
C^{15}
\end{array}$$

$$\begin{array}{c}
C^7 \\
C^7
\end{array}$$

10

## wherein in the moiety I' of compound I

15

each bond between between C<sup>5</sup> and C<sup>6</sup>, between C<sup>6</sup> and C<sup>7</sup>, between C<sup>7</sup> and C<sup>8</sup>, between C<sup>8</sup> and C<sup>9</sup>, between C<sup>8</sup> and C<sup>14</sup> and between C<sup>14</sup> and C<sup>15</sup>, independently, is a single bond or a double bond, at least one of these bonds being a double bond, with the proviso that there is no double bond in the steroid skeleton

20

# exclusively between C5 and C6, and

#### wherein

5

10

15

R<sup>4</sup> and R<sup>4</sup> independently, are selected from the group, comprising hydrogen and methyl.

- 2. The steroid compound according to claim 1, wherein in the moiety with general formula **I'** one double bond is present between C<sup>8</sup> and C<sup>14</sup> or two double bonds are present between C<sup>8</sup> and C<sup>9</sup> and between C<sup>14</sup> and C<sup>15</sup> or two double bonds are present between C<sup>5</sup> and C<sup>6</sup> and between C<sup>7</sup> and C<sup>8</sup>.
- 3. The steroid compound according to any one of claims 1 and 2, being selected from the group comprising:

(20S)-20-[(thiomorpholin-4-yl)methyl]-4,4-dimethyl-5 $\alpha$ -pregna-8,14-dien-3 $\beta$ -ol:

WO 2005/014613 PCT/EP2004/007737

41

(20S)-20-[(thiomorpholin-4-yl)methyl]-4,4-dimethyl-5 $\alpha$ -pregna-8(14)-en-3 $\beta$ -ol:

IB

5

 $(20S)-20-[(thiomorpholin-4-yl)methyl]-5\alpha-pregna-8,14-dien-3\beta-ol:$ 

IC

(20S)-20-[(thiomorpholin-4-yl)methyl]-4,4-dimethyl-pregna-5,7-dien-3β-ol

10

WO 2005/014613

 $(20S)-20-[(thiomorpholin-4-yl)methyl]-5\alpha-pregna-8(14)-en-3\beta-ol:$ 

5 **IE**.

4. A pharmaceutical composition comprising at least one thiomorpholino steroid compound of general formula I according to any one of claims 1
- 3 and at least one pharmaceutically acceptable excipient.

10

5. The pharmaceutical composition according to claim 4, wherein the steroid compound of general formula **I** is comprised in an effective amount.

15

6. A use of the thiomorpholino steroid compound of general formula **I** according to any one of claims 1 - 3 to the preparation of a pharmaceutical composition being useful to regulate reproduction, especially meiosis.

20

- 7. The use according to claim 6 for non-in vivo use.
- 8. A use of the thiomorpholino steroid compound of general formula **I** according to any one of claims 1 3 to the preparation of a contraceptive or of a profertility drug.

PCT/EP2004/007737

9. A method of regulating reproduction, especially meiosis, comprising administering to a subject in need of such a regulation an effective amount of at least one thiomorpholino steroid compound of general formula I according to any one of claims 1 - 3.

5

10. A method for improving the possibility of an oocyte's ability to develop into a mammal, comprising contacting an oocyte removed from the mammal with the thiomorpholino steroid compound according to any one of claims 1 - 3.

10

20

- 11. A method for the preparation of (20S)-20-[(thiomorpholin-4-yl)methyl]--4,4-dimethyl-5α-pregna-8,14-dien-3β-ol, comprising
  - a) starting from (20S)-20-hydroxymethyl-pregna-4-en-3-one;

b) introducing two alkyl groups in C<sup>4</sup> by alkylation; 15

- c) reducing the keto group to a hydroxy group;
- d) protecting the resulting hydroxy group with an acyl group;
- e) introducing a  $\Delta^7$  double bond by bromination/dehydrobromination;
- f) isomerizing the dien  $\Delta^{5,7}$  to the dien  $\Delta^{8,14}$  by heating in the presence of acid;
- g) oxidizing the 17-hydroxy group to an aldehyde group;
- h) reductively aminizing the aldehyde group with thiomorpholine and removing the acyl group by reduction reaction
- 25 12. The method according to claim 11, wherein the acyl group is a benzoate group.